Formosa Pharmaceuticals (TPE:6838) Short-Term Debt: NT$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6838 Formosa Pharmaceuticals Inc TPE:6838
47 GF Score
Price NT$23.40
GF Value NT$77.58
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Formosa Pharmaceuticals Short-Term Debt?

Formosa Pharmaceuticals TPE:6838 -0.43% 47 Short-Term Debt is NT$0.00 Mil as of Mar. 2026. GuruFocus rates TPE:6838 with a GF Score™ of 47/100 and a GF Value™ of NT$77.58 (Possible Value Trap). The stock has 3 warning signs investors should review.

Formosa Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was NT$0.00 Mil.

Formosa Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Formosa Pharmaceuticals Short-Term Debt Related Terms

Formosa Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Formosa Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formosa Pharmaceuticals Short-Term Debt Chart

Formosa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Formosa Pharmaceuticals Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6838
47GF Score
Formosa Pharmaceuticals Inc TPE:6838
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$0.00 Mil mean?
Formosa Pharmaceuticals (TPE:6838) has a Short-Term Debt of NT$0.00 Mil as of Mar. 2026.
Is Formosa Pharmaceuticals' Short-Term Debt too high?
Formosa Pharmaceuticals' current Short-Term Debt is NT$0.00 Mil. Overall, Formosa Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' Short-Term Debt compare to VRTX and REGN?
Formosa Pharmaceuticals' Short-Term Debt of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Formosa Pharmaceuticals's current Short-Term Debt is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Possible Value Trap. The stock's GF Value™ is NT$77.58, compared to a current price of NT$23.40 — trading 69.8% below its estimated fair value. The current Short-Term Debt is NT$0.00 Mil. Formosa Pharmaceuticals' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current Short-Term Debt is NT$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?

Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$23.40 is trading 69.8% below its estimated GF Value™ of NT$77.58. GuruFocus considers Formosa Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TPE:6838:

  • Short-Term Debt: NT$0.00 Mil
  • GF Value™: NT$77.58 vs. price of NT$23.40 (69.8% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formosa Pharmaceuticals Business Description

Address No. 57, Fuxing North Road, 8th Floor-6, Songshan District, Taipei, TWN, 105
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
47GF Score

Get the complete analysis for TPE:6838

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.40
Price
NT$77.58
GF Value